SEC Filing Summary for Gary Charles Robb

Gary Charles Robb, Chief Business Officer of CORCEPT THERAPEUTICS INC, reported a transaction on 2026-09-24. The transaction involved the disposal of 17,100 shares of Common Stock, with 14,056 shares remaining. Additionally, 5,000 shares were acquired, bringing the total to 20,571 shares, held indirectly through a custodial account for a child. Another acquisition of 5,000 shares was also reported, with 20,571 shares held indirectly. The report also indicates 39,716 shares are held indirectly through the Gary Charles Robb TTE Robb Revocable Trust, of which Robb is the trustee. The shares underlying unvested restricted stock awards are included in the reported share counts, with vesting occurring one year from the grant date under certain conditions. The filing is Form 4, and the signature date was 2026-09-28.